Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel
treatment to block complement activation in the kidneys and thereby attenuate renal disease
and stabilize or improve kidney function and compare it to the currently used treatment with
the angiotensin converting enzyme inhibitor, enalapril, in patients with the
complement-mediated renal disease C3 glomerulopathy. Patients will be randomized to one or
the other treatment for the first 6 months and then switch to the other treament for the
following 2.5 years. Treatment will continue for altogether 3 years for each patient.